Erin E. Mulvihill, PhD, is a Scientist and Director of the Energy Substrate Metabolism Research Laboratory at the University of Ottawa Heart Institute. She is also an Assistant Professor, Department of Biochemistry, Microbiology and Immunology, in the Faculty of Medicine, at the University of Ottawa.
Dr. Erin Mulvihill obtained her PhD in Biochemistry from the University of Western Ontario under the supervision of Murray Huff, PhD, in the Vascular Biology Group at the Robarts Institute. During her doctoral studies, Dr. Mulvihill’s work focused on understanding how interventions with pharmacotherapy and naturally-occurring flavonoid compounds can target hepatic lipoprotein production and prevent the formation of atherosclerotic lesions.
Dr. Mulvihill completed postdoctoral training under the supervision of Dr. Daniel Drucker, a notable leader in the fields of incretin biology and Type 2 Diabetes at the Lunenfeld-Tanenbaum Research Institute, located at Mount Sinai Hospital. During her postdoctoral tenure, Dr. Mulvihill led a detailed molecular assessment of how DPP4 inhibitors lower blood glucose using a combination of mouse genetics and pharmacology. She has also been involved in understanding how incretin therapies impact cardiovascular disease using a number of experimental mouse models. She was awarded a Lunenfeld-Tanenbaum Research Institute Innovation Grant in 2016.
Dr. Mulvihill joined the University of Ottawa and University of Ottawa Heart Institute in July 2017. Her program is funded by the Canadian Institutes of Health Research, Diabetes Canada, the Natural Sciences and Engineering Council of Canada, the Diabetes Merck Investigator Studies Program, and the Canada Foundation for Innovation.
Dr. Mulvihill’s has an expertise in lipids and lipoproteins, models of diabetes and cardiovascular disease, intestinal biology and mouse genetics. Her research program contributes to improving our understanding of the molecular events which contribute to metabolic and cardiovascular disease.
See current publications list at PubMed.
- Circulating Levels of Soluble Dipeptidyl Peptidase-4 Are Dissociated from Inflammation and Induced by Enzymatic DPP4 Inhibition Elodie M. Varin, Erin E. Mulvihill, Jacqueline L. Beaudry, Gemma Pujadas, Shai Fuchs, Jean-François Tanti, Sofia Fazio, Kirandeep Kaur, Xiemin Cao, Laurie L. Baggio, Dianne Matthews, Jonathan E. Campbell, Daniel J. Drucker Cell Metabolism [Epub ahead of print]
- GLP-1 Receptor Expression Within the Human Heart. Baggio LL, Yusta B, Mulvihill EE, Cao X, Streutker CJ, Butany J, Cappola TP, Margulies KB, Drucker DJ. Endocrinology. 2018 Apr 1;159(4):1570-1584.
- Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2. Mulvihill EE. Curr Opin Lipidol. 2018 Apr;29(2):95-103.
- Dipeptidyl peptidase inhibitor therapy in type 2 diabetes: Control of the incretin axis and regulation of postprandial glucose and lipid metabolism. Mulvihill EE. Peptides. 2018 Feb;100:158-164.
- Inactivation of the Glucose-Dependent Insulinotropic Polypeptide Receptor Improves Outcomes following Experimental Myocardial Infarction. Ussher JR, Campbell JE, Mulvihill EE, Baggio LL, Bates HE, McLean BA, Gopal K, Capozzi M, Yusta B, Cao X, Ali S, Kim M, Kabir MG, Seino Y, Suzuki J, Drucker DJ. Cell Metab. 2018 Feb 6;27(2):450-460.e6.
- The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice. Baggio LL, Ussher JR, McLean BA, Cao X, Kabir MG, Mulvihill EE, Mighiu AS, Zhang H, Ludwig A, Seeley RJ, Heximer SP, Drucker DJ. Mol Metab. 2017 Nov;6(11):1339-1349.
- Cellular Sites and Mechanisms Linking Reduction of Dipeptidyl Peptidase-4 Activity to Control of Incretin Hormone Action and Glucose Homeostasis. Mulvihill EE, Varin EM, Gladanac B, Campbell JE, Ussher JR, Baggio LL, Yusta B, Ayala J, Burmeister MA, Matthews D, Bang KWA, Ayala JE, Drucker DJ. Cell Metab. 2017 Jan 10;25(1):152-165.
- Citrus Flavonoids as Regulators of Lipoprotein Metabolism and Atherosclerosis. Mulvihill EE, Burke AC, Huff MW. Annu Rev Nutr. 2016 Jul 17;36:275-99.
- Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat-Fed Diabetic Mice. Mulvihill EE, Varin EM, Ussher JR, Campbell JE, Bang KW, Abdullah T, Baggio LL, Drucker DJ. Diabetes. 2016 Mar;65(3):742-54.
- TCF1 links GIPR signaling to the control of beta cell function and survival. Campbell JE, Ussher JR, Mulvihill EE, Kolic J, Baggio LL, Cao X, Liu Y, Lamont BJ, Morii T, Streutker CJ, Tamarina N, Philipson LH, Wrana JL, MacDonald PE, Drucker DJ. Nat Med. 2016 Jan;22(1):84-90.